In Brief
Cytotoxic T lymphocytes (CTLs) are important to eliminate virus-infected cells and cancer cells from the body. Ahrends et al. reveal that CD4 + T cells help CTLs acquire their ability to perform this task through a specific gene program that involves the downregulation of coinhibitory receptors and increased motility and migration capacities. undergo CTL effector and memory differentiation after their activation in lymphoid organs. These differentiation processes involve transcriptional and epigenetic changes and are regulated by pairs of transcription factors. Among these, T-bet and Eomes together dictate CTL identity, wherein T-bet promotes a short-lived effector state and Eomes favors a memory precursor state. Id2 and Blimp-1 contribute to the generation of short-lived, terminally differentiated effector CTLs, whereas Id3 and Bcl-6 contribute to the generation and maintenance of memory CTLs (Kaech and Cui, 2012; Weng et al., 2012) .
During priming, CD4 + T cells can promote clonal expansion and effector and memory differentiation of CD8 + T cells (Arens and Schoenberger, 2010; Bevan, 2004; Castellino and Germain, 2006) . For this reason, therapeutic vaccines include MHC class II binding ''helper'' peptides (Melief et al., 2015) . A dendritic cell (DC) acts as the intermediate to deliver CD4 + T cell help to a CD8 + T cell. Intravital imaging studies have revealed this cellular scenario in vivo (Eickhoff et al., 2015; Hor et al., 2015) . CD4 + and CD8 + T cells initially find their antigen on distinct DC populations, but in a second step of T cell priming, they simultaneously interact with the same lymph node-resident XCR1 + DC. CD4 + T cell help for the CTL response is most likely delivered at this cellular interface, since depletion of XCR1 + DCs abrogated the memory CTL response (Eickhoff et al., 2015) .
When a CD4 + T cell recognizes antigen on a DC, it upregulates CD40 ligand and triggers CD40 on the DC. CD40 signaling upregulates CD80 and CD86 and CD70 on the DC that in turn trigger the costimulatory receptors CD28 and CD27 on the CD8 + T cell.
The DC also makes particular cytokines, including IL-15, in response to CD4 + T cell contact. These costimulatory and cytokine signals emanating from the DC are important for delivery of CD4 + T cell help for the CTL response (Ahrends et al., 2016; Arens and Schoenberger, 2010; Feau et al., 2012; Greyer et al., 2016) . Memory CTL differentiation always requires CD4 + T cell help, but in many infection models the primary CTL response appeared helper independent. Generally, it is assumed that the primary CTL response requires CD4 + T cell help only when pattern recognition receptors (PRR) and/or inflammatory signals are lacking (Bevan, 2004; Castellino and Germain, 2006) . However, these studies have not examined the effects of CD4 + T cell help on CTL effector differentiation globally at the molecular level. We here present the gene expression signatures that discern ''helped'' from ''non-helped'' CTLs, as identified in vaccination and virus infection settings. The ''help'' signatures derived from both settings have evident commonalities and identify a general program of CTL effector differentiation resulting from CD4 + T cell help. This program includes not only suspected but also many novel aspects of CTL effector differentiation that prove to be essential for an optimal anti-tumor response. Moreover, we identify CD27 costimulation as the key pathway that installs the help program in primed CD8 + T cells.
RESULTS
Transcriptional Signature of CD4 + T Cell Help in CD8 +
T Cells
To examine how CD4 + T cell help impacts on the CTL response, we have primarily used a mouse model of therapeutic anticancer vaccination (Ahrends et al., 2016) . A comparative setting was created using two DNA vaccines that encode the human papilloma virus (HPV) E7 protein either with the immunodominant, MHC class I-restricted epitope E7 48-57 alone (''no help'') or in conjunction with exogenous, HPV-unrelated MHC class IIrestricted helper epitopes (''help'') ( Figure S1A ). As shown before (Ahrends et al., 2016) , helper epitopes significantly increased the generation of E7-specific-and Granzyme B + CD8 + T cells and their intrinsic CTL activity (Figures S1B-S1D).
To reveal the molecular basis of CD4 + T cell help for the CTL response, we performed mRNA deep sequencing (RNaseq) of ''helped'' versus ''non-helped'' CD8 + T cells. E7-specific CD8 + T cells were isolated from spleen at day 10 ( Figures 1A and 1B) when the response peaks ( Figure S1B ) and functional CTLs are present ( Figures S1C and S1D ). Statistical analysis of normalized transcript read counts indicated differential expression of 969 (C) MA plot depicting results of comparative transcriptome analysis of E7-specific CD8 + T cells (3 samples, n = 3 each). Normalized read counts were analyzed for log2 fold change (FC) differential expression and log2 count per million (CPM). Blue and red dots indicate transcripts with significant differential expression. (D) Enrichment map (BiNGO) classifying differentially expressed genes into functional categories. Nodes represent biological process terms from Gene Ontology (see Table S1 ). Highly connected terms were grouped and annotated manually by a shared term. Figure S1 and Table S1 .
genes in E7-specific CD8 + T cells ( Figures 1C, S1E , and S1F) (GEO: GSE89665). These genes encode a great diversity of proteins ( Figure S1F ), assigned to a multitude of cellular functions, including ''lymphocyte activation,'' ''lymphocyte differentiation,'' and ''cell motility and migration'' ( Figure 1D ; Table S1 ).
We also examined the impact of CD4 + T cell help in a virus infection model. Mice were infected with the acute lymphocytic choriomeningitis virus (LCMV) strain Armstrong and depleted for CD4 + T cells (no help) or not (help) (Figures 1E and S1G ).
CD8
+ T cells specific for GP [33] [34] [35] [36] [37] [38] [39] [40] [41] in H-2D b were isolated from the spleen at the peak of the response ( Figures  1F and S1G ) and analyzed by RNaseq. A total of 976 genes was differentially expressed in virus-specific CD8 + T cells (Figures 1G , S1H, and S1I) (GEO: GSE89665). Gene set enrichment analysis (GSEA) ( Figure 1H ) and hierarchical clustering (Figure S1J ) indicated a significant overlap in the transcripts that constituted the help signature in the vaccination and virus infection settings (see also Table S1 ). Accordingly, the differentially expressed transcripts in the infection setting were assigned to a similar diversity of cellular functions as in the vaccination setting ( Figure S1K ). In conclusion, we revealed by transcriptomics that CD4 + T cell help during priming instills a specific gene expression program into CTLs, also when they are primed in presence of pathogen-derived signals. Table S2 ), which validated the dataset. CD4 + T cell help promotes cytotoxic function of CTLs on a per cell basis ( Figure S1D ) and accordingly, it significantly upregulated the cytotoxic effector molecules TNF, FASL, GZMB, and IFN-g at the mRNA and protein level (Figures 2A and  2B ). IL-2 and the IL-2 receptor a chain (CD25) and TNFRSF9 (CD137, 4-1BB) that are important for CTL survival and memory formation (Croft, 2009) were also upregulated at the mRNA and protein level (Figures 2A and 2B Kaech and Cui, 2012) . This suggested that help promoted both cell fates, as supported by presence in the gene expression dataset of transcription factors involved in effector and memory T cell differentiation. In helped E7-specific CD8 + T cells, T-BET and IRF4 protein expression ( Figure 2F ) was higher than in non-helped cells, while TCF7 (= TCF1), ID3, and EOMES protein expression (Figures 2A and  2F ) was lower. In the dataset from the virus infection model, IPA also identified among differentially expressed proteins the functional categories ''T cell response,'' ''cytotoxicity of cells,'' ''activation of T lymphocytes,'' and ''differentiation of helper T cell lymphocytes'' ( Figure S2A , Table S2 ). Furthermore, the hits included TNF, FASL, PRF1, and GZMB. In line with the promotion of both SLEC and MPEC differentiation by CD4 + T cell help, certain relevant molecules, including transcription factors, were differentially expressed in both datasets.
+ T Cells Primed in Absence of CD4 + T Cell Help Are
Functionally Impaired by Coinhibitory Receptors One of the striking effects of CD4 + T cell help was the downregulation on helped E7-specific CD8 + T cells of coinhibitory receptors. This was observed both in the vaccination model ( Figure 2A ) and the infection model ( Figures S2 and S3B ) and included PD-1 (PDCD1), BTLA, LAG3, and CD200R (and its ligand CD200). Flow cytometry of cells derived from spleen, blood, and draining lymph node (dLN) indicated higher protein expression of these coinhibitory molecules on non-helped as compared to helped CD8 + T cells after vaccination ( Figures 3A and 3B ). The cellintrinsic expression level of these receptors was increased, while the frequencies of cells expressing them were not different in the help versus no-help setting ( Figure S3A ). To examine whether the coinhibitory receptors impeded priming of non-helped CD8 + T cells, we vaccinated mice with the no-help vaccine alone or together with blocking mAb to PD-1, BTLA, or LAG3. Blocking of BTLA slightly increased the magnitude of the E7-specific CD8 + T cell response, but blocking of PD-1 or LAG3 had no effect ( Figure 3C ). Next, we tested whether the coinhibitory receptors impeded the cytotoxic function of non-helped CTLs. E7-specific CD8 + T cells, isolated at day 10 after vaccination, were tested in vitro for killing of E7 49-57 peptide-pulsed target cells ( Figure 3D ). At a 1:1 effector-target ratio, helped CTLs were significantly more effective than non-helped CTLs. The CTL activity of non-helped CD8 + T cells improved significantly when PD-1, LAG3, or BTLA were blocked by specific mAb, while that of helped CTL was hardly affected ( Figure 3D ). CD200R blocking had no effect. At a 1:1 effector-target ratio, the activity of non-helped CTLs was similar to that of helped CTL when PD-1 or BTLA were blocked. However, at a 1:5 effector-target ratio, helped CTLs were still more effective, in line with the fact that non-helped CTLs express lower amounts of cytotoxic molecules on a percell basis ( Figure 2 ). We conclude that PD-1, BTLA, and LAG3 inhibit CTL effector function of non-helped CTLs in a reversible manner. We also examined how coinhibitory receptors impacted the in vivo anti-tumor activity of non-helped E7-specific CD8 + T cells. TC-1 tumor cells expressing HPV E7 protein were implanted s.c. and 5 days later, mice were vaccinated with help or no-help vaccine alone or in combination with blocking mAb to PD-1, BTLA, or LAG-3, or the triple combination ( Figure 3E ). All mice that had received the help vaccine survived long-term, while mice that had received no-help vaccine had to be sacrificed between day 20 and 30 due to tumor outgrowth ( Figure 3E ). Blocking of BTLA improved tumor control, while blocking of PD-1 or LAG3 alone had no effect. Blocking all three molecules together was most beneficial (Figure 3E) , indicating that the coinhibitory receptors partly complemented each other's functions. Taken together, these data show that CD8 + T cells primed in the absence of CD4 + T cell help upregulate various coinhibitory receptors that directly inhibit CTL effector function and thereby undermine anti-tumor efficacy. Table S3 ). IPA assigned a host of differentially expressed molecules from both the vaccination and infection settings to the functional category ''leukocyte migration'' (Figures 4A and S4; Table S3 ). In the vaccination setting, there was also a large number of differentially expressed molecules assigned to the functional category ''invasion of cells'' (Figure 4A ). These data suggested that CD4 + T cell help improves the capacity of CTLs to migrate to non-lymphoid ''effector'' tissue. We tested this in our TC-1 tumor model. Effector T cells are known to extravasate under guidance of chemokines presented by endothelial cells in inflamed tissue (Nolz et al., 2011) . TC-1 cells form upon s.c. implantation a dense mass that is enveloped by blood vessels ( Figure 4B ), as identified in immunohistochemistry (IHC) by the endothelial marker CD31. The tumor border was identified by the presence of Vimentin + tumor cells ( Figure 4C ). In the absence of vaccination, TC-1 tumors were devoid of CD8 + T cells ( Figure 4C ). In mice that had received help vaccine, E7-specific CD8 + T cell infiltration into the tumor peaked (30%) at day 20 when tumor volume was decreasing ( Figure 4D ). 5 days later, tumors were no longer palpable. In mice that had received no-help vaccine, E7-specific CD8 + T cell infiltration into the tumor had reached only 3% at day 20 ( Figure 4D ). Thereafter, infiltration increased up to 20%, but tumor outgrowth was not controlled ( Figure 4D ). To examine whether helped versus nonhelped CTLs differed in cell-intrinsic migratory potential, we performed adoptive transfer experiments. E7-specific CD8 + T cells, isolated at day 10 from mice that had received help or no-help vaccine, were injected in equal numbers into two groups of TC-1 tumor-bearing mice. At 48 hr after adoptive transfer, there was a significantly higher density of intra-tumoral CD8 + T cells in mice that had received helped CTLs as compared to mice that had received non-helped CTLs ( Figure 4E ). Thus, CTLs primed in the presence of CD4 + T cell help have better, cell-intrinsic, abilities to traffic to the tumor site.
CD4 + T Cell Help Improves Extravasation Potential of
CTLs by Upregulation of CXCR4 and CX3CR1 Helped CD8 + T cells upregulated mRNA encoding various chemokine receptors. In the vaccination model, these included CXCR4 and CX3CR1 ( Figure 4A ) that have been implicated in T cell trafficking to tumors (Dunussi-Joannopoulos et al., 2002; Siddiqui et al., 2016) . Protein levels of CXCR4 and CX3CR1 were also significantly higher on helped as compared to nonhelped CD8 + T cells ( Figure 5A ). To determine the functional relevance of CXCR4 and CX3CR1, we tested the cell-intrinsic capacity of ex vivo isolated helped versus non-helped CD8 + T cells to migrate toward their respective ligands CXCL12 and CX3CL1 in vitro. Among helped CD8 + T cells, about 20% migrated toward CXCL12 and 50% toward CX3CL1 ( Figure 5B ).
The migration efficacy was reduced to about 5% when CXCR4 or CX3CR1 were blocked by their respective small-molecule inhibitors: AMD3100 or 18a. Non-helped CD8 + T cells migrated with an efficiency of about 5%, which was not affected by blocking of CXCR4 or CX3CR1 ( Figure 5B ), indicating that these chemokine receptors did not contribute to the migration of non-helped CD8 + T cells. Helped CD8 + T cells also migrated significantly more efficiently through an endothelial cell layer than non-helped CD8 + T cells ( Figure 5C ).
Next, we examined whether CXCR4 and CX3CR1 contributed to the superior capacity of helped CTLs to reach the tumor site. For this purpose, ex vivo sorted helped and non-helped E7-specific CD8 + T cells were injected in equal numbers into distinct groups of tumor-bearing recipient mice. Tumors showed expression of both CX3CL1 and CXCL12 ( Figure 5D ). Two groups of mice that had received helped CD8 + T cells were treated with inhibitor AMD3100 or 18a. At 48 hr after adoptive T cell transfer, T cell infiltration into TC-1 tumors was evaluated by IHC for CD8 ( Figure S5 ). The density of CD8 + T cells in the tumor was significantly higher in mice that had received helped as compared to non-helped CD8 + T cells and this was significantly reduced by CXCR4 or CX3CR1 inhibition ( Figure 5E ). These data indicate that CXCR4 and CX3CR1 assist helped CD8 + T cells in reaching the tumor. To examine whether helped CD8 + T cells depended on CXCR4 and CX3CR1 for their anti-tumor activity, tumor-bearing mice received help or no-help vaccine either alone or combined with AMD3100 and 18a. The curative effect of the help vaccine was significantly reduced upon combined blocking of CXCR4 and CX3CR1, while the mean survival of the mice that had received no-help vaccine was not affected ( Figure 5F ). Taken together, these data show that expression of CXCR4 and CX3CR1 as a result of CD4 + T cell help increases the potential of CTLs to reach a tumor site and to consequently control the tumor.
CD4 + T Cell Help Promotes the Ability of CTLs to Digest Extracellular Matrix and Invade Tissues
It can also be expected that efficacy of CTLs depends on their ability to penetrate into effector tissues (Chen and Mellman, 2013) . Matrix metalloproteases (MMPs) digest diverse extracellular matrix components and are therefore important in tissue invasion. They are well-known attributes of tumor cells but receive less attention in T cell function. The transcriptome of helped CD8 + T cells in the vaccination model had a clear ''invasion'' signature, in that transcripts encoding MMP-8, -9, -25, ADAM8 were significantly upregulated, while the endogenous MMP inhibitor protein TIMP2 was significantly downregulated (Figure 4A) . Also, genes encoding ELANE and PLAUR, known to degrade ECM, were upregulated in helped CD8 + T cells. To assess the invasive potential of helped versus non-helped CTLs, we performed in vitro transwell assays with CTLs isolated from vaccinated mice. Helped CTLs migrated significantly more efficiently through a collagen layer than non-helped CTLs (D) Numbers of E7-specific CD8 + T cells in indicated subsets, based on flow cytometric analysis shown in (E).
(E) Primary flow cytometric analysis for CD127 and KLRG1. Data are from one experiment representative of three experiments with n = 3-6. Error bars indicate SD, *p < 0.05, **p < 0.005, ***p < 0.001, and ****p < 0.0001 (unpaired two-tailed Student's t test). See also Figure S2 .
( Figure 5G ). The migration capacity of helped CTLs was reduced to that of non-helped CTLs in the presence of pan-MMP inhibitor GM6001, while the migration capacity of non-helped CTLs was not affected ( Figure 5G ). This result indicated that CD4 + T cell help enables CTLs to digest and migrate through extracellular matrix by virtue of MMP activity. We next investigated the invasive capacity of CTLs in a TC-1 tumor setting. To determine the extent of tumor invasion quantitatively by IHC, we used the tumor-associated CD31
+ blood vessels as a reference point ( Figure 4C ). Helped CTLs had a significantly greater capacity to penetrate into tumors than nonhelped CTLs ( Figure 5H ). Almost 80% of all non-helped CTLs were located at the tumor border, while helped CTLs were much more dispersed throughout the tumor (Figures 5H-5J) . (E) CD45.2 + donor mice were vaccinated and E7-specific CD8 + T cells were isolated at day 10 from spleen. They were adoptively transferred in equal numbers to 
(legend continued on next page)
Tumor invasion by helped CTLs relied on MMPs, as it was significantly reduced in mice treated with MMP inhibitor GM6100 ( Figures 5H-5J) . Thus, CD4 + T cell help enables CTLs to invade non-lymphoid (epithelial) tissue by virtue of their enhanced MMP activity.
Installation of the Transcriptional Program of CD4 + T Cell Help Depends on CD27-CD70 Costimulation
We have previously shown in the vaccination model that CD27-CD70 costimulation is very important in the delivery of CD4 + T cell help, as read out by various cellular aspects of the CTL response (Ahrends et al., 2016) . We here examined the effects of the CD27-CD70 pathway by transcriptomic analysis. For this purpose, we created two comparative settings: no-help vaccination with or without CD27 agonism or help vaccination with or without CD70 blocking ( Figure 6A ). CD27 costimulation in the absence of help altered the expression of 1,120 genes in E7-specific CD8 + T cells. Strikingly, the gene expression pattern obtained was highly similar to that instilled by CD4 + T cell help ( Figure S6 ; Table S1 ) and thus a diversity of functional processes was instilled into CD8 + T cells ( Figure 6B ; Table S1 ). Gene-set enrichment analysis further underlined that CD27-CD70 costimulation is a key effector pathway of CD4 + T cell help for the CTL response: CD27-regulated genes, identified upon treatment with CD27 agonist mAb, were significantly enriched for help signature genes ( Figure 6C ), while CD27-independent genes, identified upon treatment with anti-CD70 blocking mAb, were enriched in the no-help signature ( Figure 6D ). Signature genes regulated by the CD27/CD70 pathway were similarly enriched in the help signature derived from the virus infection setting (Figures S6C and S6D ). Figure 6E highlights for a number of relevant molecules that CD27 agonism recapitulated the effect of help in many but not all cases. CD70 blocking in the help setting mirrored the effect of CD27 agonism in the no-help setting, indicating the specificity of the effects ( Figure 6E ). In vitro, CD27 engagement downregulated PD-1, BTLA, and LAG3 on non-helped CTLs that had been isolated ex vivo. It did not affect expression of CD200R ( Figure 6F ). In vitro CTL activity was also significantly improved on a per cell basis (Figure 6G) . In vivo treatment with CD27 agonist mAb in the nohelp vaccination setting significantly improved tumor control and overall survival of the mice ( Figure 6H ). Tumor control was CTL mediated, since it was abolished when mice were depleted for CD8 + T cells. CD8 + T cell depletion did not affect tumor control and overall survival of non-vaccinated mice, indicating that TC-1 cells do not raise a CTL response by themselves (Figure 6H) . Together, these data indicate that the transcriptional program instilled into responder CD8 + T cells downstream of CD4 + T cell help is largely but not exclusively dependent on CD27-CD70 costimulation.
Delivery of CD4 + T Cell Help Requires CD27 on CD8
+ T Cells and CD70 on DCs Our data argue that CD27 agonist mAb in the no-help vaccination setting directly acts on antigen-specific CD8 + T cells, since we have previously shown that there is no CD4 + T cell response to the no-help vaccine (Ahrends et al., 2016) . To examine this directly, we made use of ovalbumin (OVA)-specific OT-I T cells that were either wild-type (WT) or genetically deficient for CD27 (Peperzak et al., 2010 Figure 7A ). In the help setting, Cd27 À/À OT-I
T cells responded to a significantly lesser extent than did WT OT-I T cells and the endogenous OVA-specific CD8 + T cells of the WT recipient ( Figure 1B ). In the no-help setting, Cd27
and WT OT-I T cells and endogenous OVA-specific CD8 + T cells of the WT recipient showed comparable, low responses ( Figures 1B and S7A ). Moreover, Cd27 À/À OT-I T cells, but not WT OT-I T cells, isolated at day 10 after help vaccination expressed significantly higher levels of coinhibitory receptors PD-1, BTLA, and LAG-3 and lower levels of KLRG1, CD127, IFN-g, GZMB, T-BET, and CX3CR1 when compared to endogenous OVA-specific CD8 + T cells of the WT recipient ( Figures 7C,   7D , and S7B). CD200R and CXCR4 upregulation by help did not depend on the presence of CD27 on CD8 + T cells. These data indicate that CD4 + T cell help is to a large extent delivered via CD27 on antigen-specific CD8 + T cells.
We next tested whether CD70 on DCs was required to transmit the CD4 + T cell help signal. For this purpose, we compared the response of WT OT-I T cells to OVA 257-264 peptide-pulsed WT versus Cd70 À/À DCs ( Figure 7E ; Coquet et al., 2013) . To mimic the CD4 + T cell help signal, the DCs were stimulated with CD40-agonist mAb in vitro prior to transfer, which upregulated CD86 and, in the case of WT DCs, also CD70 ( Figure S7C ). OT-I T cells expanded only in response to CD40-stimulated DCs and the response was significantly higher to WT as compared to Cd70 À/À DCs ( Figures 7F and S7D) . Furthermore, expression of help signature molecules was affected by the absence of CD70, except for CD200R and CXCR4 that were not regulated by CD27 ( Figure 7G ). To test whether CD27 on CD4 + T cells was required for the delivery of help, we adoptively transferred CD45.1 + WT OT-I T cells into CD45.2 + Cd27 À/À recipients. In these recipients, CD27 on CD4 + T cells cannot participate in the OT-I T cell response (Figure 7H) . OVA-specific CD8 + T cells significantly profited from CD4 + T cell help in terms of magnitude of the response ( Figures   7I and S7E) . Moreover, the help signature molecules were regulated in the same manner as shown before ( Figure 7J Error bars indicate SD, *p < 0.05, **p < 0.005, ***p < 0.001, and ****p < 0.0001 (unpaired two-tailed Student's t test in B, C, and G-H, one-way ANOVA test in E, and log-rank test in F). See also Figure S5 . (legend continued on next page) CD27 on CD4 + T cells was not essential for the delivery of help for the primary CTL response. Taken together, these data indicate that CD27 on CD8 + T cells and CD70 on DCs are required for delivery of CD4 + T cell help for the CTL response.
DISCUSSION
It is important to understand the cellular functions and molecular programs underlying CD4 + T cell help for the CTL response. Molecules that are part of the help program may serve as diagnostic markers or therapeutic targets in vaccination or other approaches that aim to influence the CTL response in cancer, auto-immunity, or infectious disease. To fulfill their purpose as CTLs, CD8 + T cells must ''succeed'' at every step on their path: they must encounter antigen on activated DCs, clonally expand, and differentiate into CTLs. The CTLs must go into circulation, extravasate at inflammatory sites, and penetrate into the target tissue. They must recognize their target cells and kill them, therein overcoming potential resistance. In cancer, CD8 + T cells encounter many hurdles on this path (Chen and Mellman, 2013) . Our study reveals that CD4 + T cell help during priming gives CTLs the intrinsic capacities to overcome these hurdles.
The central model explored in this study has been therapeutic anti-cancer vaccination. However, we also demonstrated that the primary CTL response to virus infection, previously classified as helper independent, is qualitatively improved by CD4 + T cell help that instills diverse functional properties into CTLs in the same way as in weakly adjuvanted vaccination. In the vaccination model, there are no PRR signals. The vaccine protein is expressed by transfection of DNA into keratinocytes. The cells may experience ''danger'' as a result of cytoplasmic DNA delivery and may report this in the form of inflammatory cytokines to DCs in the dLN. In the virus infection model, we saw many similar changes in gene expression, but also differences that are expected to reflect a response to the overt inflammatory signals coming from infected cells and innate immune cells in this setting. The transcriptomes obtained primarily related to CTL effector differentiation, rather than clonal expansion, since we analyzed the cells at the peak of the primary response. Upregulation of Granzymes, Perforin, IFN-g, and death receptor ligands in the vaccination and/or virus infection setting testified to improved CTL effector differentiation. Further study in the vaccination setting demonstrated that CD4 + T cell help increased SLEC as well as MPEC formation. In both settings, we found an upregulation of the IL-7 receptor (CD127), in line with MPEC formation. We also observed upregulation of IL-2 and the IL-2 receptor (CD25) in the vaccination setting. This agrees with CD4 + T cell help instigating autocrine IL-2 signaling that promotes both SLEC and MPEC differentiation (Pipkin et al., 2010; Williams et al., 2006) . IL-2 signaling also promotes CTL survival in nonlymphoid tissues (D'Souza et al., 2002; Mitchell et al., 2010) . In both vaccination and virus infection settings, CTLs primed in the absence of CD4 + T cell help expressed multiple coinhibitory receptors, including PD1, BTLA, and LAG3 that are key targets in cancer immunotherapy (Chen and Mellman, 2013) . CTLs raised in absence of CD4 + T cell help proved less effective ''killers'' for this reason. Tumor-specific CD8 + T cells present in the blood of melanoma patients are primarily PD-1 + (Gros et al., 2016) . We propose that circulating PD-1 + CD8 + T cells in cancer patients reports priming in the absence of CD4 + T cell help. ''Dysfunction'' of tumor-specific T cells is reportedly initiated early during tumorigenesis (Schietinger et al., 2016) Figure S5 ), penetrating deeply into the tumors, but in significantly reduced numbers. CX3CL1 (Fractalkine) and the CXCR4 ligand CXCL12 (SDF) are expressed in a great variety of human cancers (http://v15.proteinatlas.org) and are known CTL chemoattractants that promote anti-tumor immunity (Dunussi-Joannopoulos et al., 2002; Nishimura et al., 2002; Siddiqui et al., 2016) . Thus CD4 + T cell help during priming promoted the ability of CTLs to reach the tumor site by CX3CR1 and CXCR4 upregulation. CD4 + T cell help delivered in the target organ in the form of IFN-g can also optimize CTL infiltration by CTLs (Nakanishi et al., 2009 ). However, in our vaccination model with tumor-unrelated helper epitopes, no tumor-specific CD4 + T cells are generated, so intra-tumoral help is lacking.
In multiple cancer types, CD8 + T cells were found to be excluded from the vicinity of tumor cells, which correlates to a poor clinical outcome (Galon et al., 2006) and a negative response to anti-PD1 treatment (Tumeh et al., 2014) . T cell exclusion has been attributed to impeded T cell extravasation (Chen and Mellman, 2013) but collagen-rich structures can also limit T cell penetration into the tumor (Salmon et al., 2012) . T cells can produce MMPs (Owen et al., 2003) that are required for T cell movement through collagen-rich structures (Wu et al., 2007) . Our results show that CD4 + T cell help endows CTLs with tumor-invasive capacity in the form of MMP activity, thus overcoming a key barrier in tumor control (Chen and Mellman, 2013) .
Our results show unambiguously that CD27 on CD8 + T cells and CD70 on DCs relay many effects of CD4 + T cell help. Cytokines made by DCs also play a role in CD4 + T cell help for the CTL response, as recently demonstrated for IL-15 (Greyer et al., 2016) and earlier for IL-12 (Mescher et al., 2006) . In our datasets, not all molecules regulated by CD4 + T cell help were regulated by CD27, leaving room for an independent contribution by cytokine signaling. Furthermore, CD27 costimulation may exert certain help effects indirectly via cytokine receptor signaling. For example, the IL-12 receptor b chain was upregulated both in Figure S6 and Table S1 . et al., 2009). We found here that CD27 on CD4 + T cells does not play a major role in relaying the help signal for the primary CTL response. Our findings argue in favor of CD27 agonism to optimize anti-tumor immunity. In those cases where CD4 + T cell help is deficient, such an intervention is expected to promote the generation of an optimal CTL response, both in terms of quantity and quality.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq Analysis RNA-seq reads were aligned to the GRCm38_77 build of the Mus musculus genome using Tophat (version 2.0.12). Only uniquely mapped reads were used for gene expression analysis. Differential expression analysis was performed using edgeR in R (Bioconductor). Read counts were normalized using edgeR and RPKM values were calculated. Differential mRNA expression was considered significant at FDR < 0.01. MDS and MA plots were generated using edgeR. GSEA was carried out using ROAST. Enrichment maps were generated using the BiNGO plugin in Cytoscape with P-and Q-value cut-off of 0.001. Hierarchical clustering was performed using Qlucore. Functional classification of the genes was performed using IPA software (QIAGEN).
Statistical Analysis
Data was analyzed with GraphPad Prism software using unpaired two-tailed Student's t, Log-rank, edgeR, ROAST or One-way ANOVA test. Error bars in figures indicate SD. A P value < 0.05 was considered statistically significant; *p < 0.05, **p < 0.005, ***p < 0.001 and ****p < 0.0001.
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